- Poster presentation
- Open access
- Published:
Clinical and epidemiological risk factors for ventilator-associated pneumonia in a cohort of critically ill patients
Critical Care volume 16, Article number: P73 (2012)
Introduction
Ventilator-associated pneumonia (VAP) represents a major infectious complication in the ICU. The aim of this study is to identify risk factors for VAP acquisition.
Methods
All patients admitted to the 18-bed ICU of our university hospital between 1 October 2009 and 31 December 2010 were enrolled on the day of VAP diagnosis. Controls were selected by our computerized database. Statistical analyses were performed using the StataICl l program.
Results
Over the study period, among 902 admissions, 100 VAP occurred. The rate of multidrug resistance (MDR) was 23%. Development of VAP was associated with a significantly longer duration of ICU stay (24 days (17 to 30) vs. 7 days (5 to 9); P < 0.001) and mechanical ventilation (19 days (13 to 20) vs. 4 days (3 to 6); P < 0.001). Overall ICU mortality was higher in the VAP population (41% vs. 29%; P = 0.09). Comparing patients affected by VAP with controls (100 matched patients), the former group was significantly more likely to be male (P < 0.001) and to be immunosuppressed (P = 0.004). In addition, VAP development was associated with higher rate of central venous catheter placements (P < 0.001), higher mean SOFA score value (P < 0.001) and previous exposure to antimicrobials (P = 0.004). Successful use of noninvasive ventilation, and trauma admission appeared as protective factors (P < 0.001). Table 1 shows independent risk factors associated with VAP acquisition in multivariate analysis.
Conclusion
VAP occurrence seems to be associated with increased morbidity and ICU mortality. NIV use, avoiding endotracheal intubation and invasive mechanical ventilation, has appeared to be effective in reducing the rate of VAP episodes, particularly in high-risk patients (severe immunosuppressed). The application of behavioural intervention bundles might represent the suitable preventive measure in settings where high rates of MDR pathogens limit the extensive use of pharmacological ones.
References
Vincent JL, et al.: Drugs. 2010, 70: 1927-1944. 10.2165/11538080-000000000-00000
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
De Pascale, G., Pennisi, M., Raggi, V. et al. Clinical and epidemiological risk factors for ventilator-associated pneumonia in a cohort of critically ill patients. Crit Care 16 (Suppl 1), P73 (2012). https://doi.org/10.1186/cc10680
Published:
DOI: https://doi.org/10.1186/cc10680